Prognostic significance of long intergenic non-protein-coding RNA 511expression in malignant tumors: A systematic review and meta-analysis

BACKGROUND: A growing number of studies have suggested that the Long intergenic noncoding RNA 00511 (LINC00511) is aberrantly expressed in multiple malignancies and is related to patient survival. Herein, we conducted a systematic review and meta-analysis to comprehensively evaluate the prognostic significance of LINC00511 in human malignancies. METHODS: Eligible studies published by March 11, 2020 were identified in 4 electronic databases including PubMed, EMBASE, Web of Science, and the Chinese National Knowledge Infrastructure. Hazard ratios and 95% confidence intervals (CIs) were used to evaluate the prognostic significance of LINC00511 expression in malignant tumors. The association between LINC00511 expression and cancer clinicopathologic features were assessed using Odds ratios (ORs) and CIs. RESULTS: A total of 13 studies, comprising 1,053 patients, were included in the meta-analysis. The calculated hazard ratio was 2.00 (95% CI: 1.59–2.52, P < .000), suggesting that higher LINC00511 expression could predict poorer overall survival in patients with malignancies. Additionally, our statistical analysis indicated that elevated LINC00511 expression closely associated with bigger tumors (OR = 2.92, 95% CI 1.65–5.18, P < .000), higher incidence of lymph node metastasis (OR = 3.46, 95% CI 2.11–5.66, P < .000) and distant metastasis (OR = 2.40, 95% CI 1.14–5.05, P = .02), poorer differentiation (OR = 1.55, 95% CI 1.11-2.16, P = .01), as well as more advanced TNM stage (OR = 3.90, 95% CI 2.70–5.63, P < .000). CONCLUSIONS: High LINC00511 expression may predict unfavorable prognosis in patients with malignancies. It should be further explored as a potential prognostic and therapeutic biomarker for human cancer.